PHS
AMLX icon

PFM Health Sciences’s Amylyx Pharmaceuticals AMLX Stock Holding History

PFM Health Sciences’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.58M Sell
143,700
-1,575
-1% -$24.4K 0.22% 84
2026
Q1 		$2.02M Buy
145,275
+10,726
+8% +$151K 0.18% 78
2025
Q4 		$1.63M Sell
134,549
-301,607
-69% -$4.1M 0.16% 71
2025
Q3 		$5.93M Sell
436,156
-296,100
-40% -$2.79M 0.46% 48
2025
Q2 		$4.69M Sell
732,256
-101,879
-12% -$496K 0.4% 42
2025
Q1 		$2.95M Buy
+834,135
New +$2.97M 0.21% 49

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

PFM Health Sciences's AMLX Position: Q2 2026 in Review

PFM Health Sciences reduced its Amylyx Pharmaceuticals (AMLX) stake by 1.1% in Q2 2026, selling an estimated $24.4K and leaving 143,700 shares worth $2.58M. The position accounts for 0.22% of the portfolio, ranked #84.

PFM Health Sciences first reported a position in AMLX in Q1 2025 and has held it in 6 quarters since. The position peaked at $5.93M in Q3 2025. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • PFM Health Sciences held 143,700 shares of Amylyx Pharmaceuticals worth $2.58M as of Q2 2026.
  • PFM Health Sciences sold 1,575 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $24.4K.
  • Amylyx Pharmaceuticals made up 0.22% of PFM Health Sciences's portfolio in Q2 2026, its #84 holding.
  • PFM Health Sciences first reported a position in Amylyx Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • PFM Health Sciences's Amylyx Pharmaceuticals position peaked at $5.93M in Q3 2025.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.